Neovasc to Report Second Quarter 2021 Financial Results on August 10, 2021
Neovasc Inc. (NASDAQ: NVCN) will announce its second-quarter financial results for 2021 on August 10, 2021. The report will be discussed in a conference call led by CEO Fred Colen and CFO Chris Clark at 4:30 PM EDT. Participants can join by phone or via the webcast available on the Neovasc investor relations website. Neovasc specializes in developing minimally invasive medical devices for cardiovascular treatments, including the Neovasc Reducer™ and Tiara™, which are designed for refractory angina and mitral valve disease, respectively.
- None.
- None.
VANCOUVER, July 27, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021. Neovasc’s President and Chief Executive Officer, Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the Company’s results at 4:30 pm EDT.
Interested parties may access the conference call by dialing (877)-407-9208 or (201)-493-6784 (International) and reference Conference ID 13721306. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at https://www.neovasc.com/investors/.
A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States (2 U.S. patients have been treated under Compassionate Use) and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com.
Investors
Mike Cavanaugh
Westwicke/ICR
Phone: +1.646.877.9641
Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Phone: +1.646.866.4012
Sean.Leous@icrinc.com
FAQ
When will Neovasc report its second-quarter earnings for 2021?
What time is the Neovasc conference call for the Q2 results?
How can I access the Neovasc earnings conference call?
What products does Neovasc specialize in?
